EssilorLuxottica Société anonyme (ENXTPA:EL) is in focus after reporting half year 2026 results and holding a board meeting to approve interim financial statements, giving investors fresh data on sales, earnings and profitability.
See our latest analysis for EssilorLuxottica Société anonyme.
The recent half-year 2026 results and board approval of the interim financials arrived as EssilorLuxottica Société anonyme’s share price has been under pressure in 2026, with a year-to-date share price return of a 35.10% decline and a 1-year total shareholder return of a 30.26% decline, even though short-term momentum has picked up with a 7-day share price return of 5.03%.
If you are weighing EssilorLuxottica Société anonyme’s latest update against other opportunities in the market, it can help to see how other healthcare-related businesses are priced and growing. A straightforward way to do that is to scan a focused set of 129 healthcare AI stocks
Bulls see EssilorLuxottica Société anonyme’s earnings progress as a chance to pick up quality after a sharp share price reset. Bears view the slump as justified. Do the current numbers point to undervaluation or fair caution?
Most Popular Narrative: 34.1% Undervalued
EssilorLuxottica Société anonyme’s most followed narrative points to a fair value of €261.48 against a last close of €172.30, which frames the current share price reset in a very different light for investors weighing the latest half year 2026 numbers.
Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
Want to understand why this narrative still reaches a fair value well above today’s share price? The core assumptions hinge on steady revenue expansion, firmer margins and a richer earnings mix that leans on premium eyewear and medical platforms rather than just volume.
Result: Fair Value of €261.48 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, EssilorLuxottica Société anonyme’s narrative also depends on smooth execution in smart eyewear and MedTech, as well as on managing cost pressures from tariffs and inflation.
Find out about the key risks to this EssilorLuxottica Société anonyme narrative.
Another View On EssilorLuxottica Société anonyme’s Valuation
The DCF narrative points to EssilorLuxottica Société anonyme trading below an estimated fair value of €261.48, and a future cash flow value of €290.39, which suggests undervaluation. Yet the current P/E of 31.8x sits well above the fair ratio of 24.5x and above the European Medical Equipment sector on 26.6x. That implies the share price already bakes in a richer earnings multiple than both peers and the level the fair ratio model suggests the market could move toward. Is this a margin of safety on cash flows, or a risk that sentiment normalises toward a lower multiple?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around EssilorLuxottica Société anonyme is clearly split, so do not wait too long to review the full picture for yourself and weigh both sides of the debate. To see how the current concerns and potential upsides line up in one place, review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond EssilorLuxottica Société anonyme?
If EssilorLuxottica Société anonyme has sharpened your focus on quality, do not stop here. The next strong idea could be just one screen away.
- Target steadier returns by scanning companies that score well on resilience and risk using the 299 resilient stocks with low risk scores.
- Look for compelling value by reviewing a curated set of 255 high quality undervalued stocks that combine quality fundamentals with appealing pricing.
- Identify potential future standouts early by checking a focused screener containing 548 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com